Juno Therapeutics beats by $0.01, beats on revs:
- Reports Q4 (Dec) loss of $0.65 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of ($0.66); revenues rose 409.6% year/year to $21.15 mln vs the $14.56 mln Capital IQ Consensus.
- Cash burn in the fourth quarter of 2016, excluding cash inflows and outflows from business development activities, was $106.6 million including $38.4 million for the purchase of property and equipment, of which $18.2 million was for the purchase of Juno's manufacturing facility.
- Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017.
- Discontinuing development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting.
- Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL.
- FY17 guidance:
- 2017 cash burn guidance of $270 million to $300 million, including $22 million to $27 million in capital expenditures.
- Operating burn estimated to be between $245 million and $275 million.
No comments:
Post a Comment